SMS Pharmaceuticals Limited has rescheduled its Board of Directors meeting from August 1, 2026, to July 31, 2026, to consider and approve the unaudited financial results for the first quarter ended June 30, 2026 (Q1FY26). The change in date was necessitated by unavoidable administrative exigencies, ensuring the timely disclosure of quarterly performance metrics to stakeholders.

The company informed the Bombay Stock Exchange and the National Stock Exchange of India Ltd. on July 29, 2026, regarding the preponement. The Board will transact the same business as previously intimated, primarily focusing on the approval of standalone and consolidated financial statements for Q1FY26. This procedural adjustment ensures compliance with regulatory timelines for result announcements.

Trading Window Status

In accordance with the Company's Code of Conduct for Prevention of Insider Trading and the amended SEBI (Prohibition of Insider Trading) Regulations, 2015, the trading window for designated persons remains closed. The closure began on July 1, 2026, and will remain in effect until August 2, 2026, inclusive. The trading window is scheduled to reopen on August 3, 2026.

Key Details

The notification was issued pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015. Thirumalesh Tumma, Company Secretary & Compliance Officer, signed the communication, confirming the adherence to insider trading regulations during the sensitive period leading up to the result announcement.

SMS Pharmaceuticals has confirmed that no members of its promoter and promoter group created any new encumbrances on shares during the financial year ended March 31, 2026. In a disclosure submitted to the stock exchanges, the company stated that no shares were pledged directly or indirectly during this period, other than those already disclosed in previous financial years. The filing was made pursuant to Regulation 31(4) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

The company provided details of the current equity shares already in encumbrance, which remain unchanged from previous disclosures. The total pledged shares are distributed among three key entities within the promoter group.

Breakdown of Pledged Shares

The following table outlines the equity shares held and the corresponding number of shares pledged by each member of the promoter group:

M/s. Potluri Infra Projects LLP holds the highest proportion of pledged shares relative to its total holding, with 73,46,420 shares encumbered out of 88,46,420 shares held. Potluri Laboratories Private Limited has its entire holding of 11,20,320 shares pledged. Mrs. Hima Bindu Potluri has pledged 30,00,000 shares out of her total holding of 1,50,08,840 shares.

The disclosure was signed by Ramesh Babu Potluri on behalf of the Promoter & Promoter Group. SMS Pharmaceuticals requested the exchanges to place the information on record.